Medicare's ACCESS pilot is live, but patients can't find which providers offer it

One month into Medicare's ACCESS pilot, a tech-enabled chronic care management program administered by CMS, patients enrolled in Medicare have no straightforward way to find out which of their providers are participating. That gap, reported by STAT health tech correspondent Mario Aguilar, is emerging as a structural friction point that could blunt the program's early impact before it has a chance to demonstrate value.

ACCESS is designed to expand Medicare reimbursement for technology-enabled chronic care services, giving providers a billing pathway for remote monitoring and digital care tools used with patients managing ongoing conditions. But with CMS not publishing a clear provider directory or lookup mechanism, beneficiaries are largely in the dark about where they can access those benefits.

A reimbursement pathway without a road map

For enterprise health systems and digital health vendors whose commercial model depends on Medicare reimbursement, the discovery problem is more than a patient experience issue. It directly affects utilization projections. If beneficiaries cannot identify participating providers, the program's reach stays narrow regardless of how many institutions actually enroll, limiting the volume data CMS will need to evaluate the pilot and decide whether to scale it.

Provider organizations that have already invested in the technology infrastructure required to participate, remote monitoring platforms, care coordination software, and clinical workflows built around connected devices, face a return-on-investment question that hinges on patient volume. A pilot that quietly enrolls providers but generates low utilization because patients never knew to ask for it is a familiar outcome in Medicare innovation programs, and one that enterprise operators have reason to monitor closely here.

The ACCESS rollout also arrives at a moment when regulators and health technology companies are actively negotiating the frameworks that will govern clinical AI more broadly, according to STAT. That parallel conversation matters operationally because many of the tools providers would deploy under ACCESS, such as remote monitoring algorithms and AI-assisted care management platforms, fall within the expanding category of AI-enabled medical devices subject to FDA oversight.

FDA's AI device pipeline has grown 83% since 2018

The scale of what FDA is now managing is significant. The agency authorized 115 AI-enabled medical device submissions in 2021, an 83% increase from 2018, according to data cited by STAT. That trajectory reflects a device market that expanded faster than the regulatory infrastructure designed to evaluate it.

The 2021 figure represented a record at the time, and the category has only grown more complex since. Devices that incorporate machine learning models, adapt over time, or draw on real-world data raise evaluation questions that the agency's traditional substantial equivalence framework was not designed to answer. The industry-regulator conversations STAT describes are, in part, an attempt to build a more durable pathway before that gap widens further.

For procurement and compliance teams evaluating clinical AI vendors, this regulatory fluidity is a material consideration. A product authorized under one framework today may face additional requirements as those frameworks evolve. Enterprise buyers who are building vendor shortlists or writing contract terms around FDA clearance should be tracking the outputs of these industry-regulator discussions, not just the clearance database.

What the convergence means for enterprise health operators

The two dynamics, a Medicare pilot with a utilization gap and an FDA authorization environment in active negotiation, are connected at the operational level. Health systems and digital health companies building around chronic care AI tools need both a clear reimbursement path and a durable regulatory status for the underlying technology. Right now, neither is fully settled.

On the CMS side, the most immediate question is whether the agency will publish a provider participation directory or take another step to make ACCESS discoverable by beneficiaries. Without that, vendors whose platforms are built on the ACCESS billing framework face a market that is structurally slower to develop than the regulatory approval alone would suggest.

On the FDA side, the pace of AI device authorizations has already forced the agency into ongoing dialogue with industry about what a workable regulatory model looks like for adaptive, software-driven products. Enterprise operators who participate in or closely follow those conversations, through comment periods, trade groups, or direct regulatory engagement, will have an informational advantage when the frameworks firm up.

What to watch next

The near-term marker for the ACCESS pilot is whether CMS moves to address the provider visibility gap, either through a formal directory, a beneficiary-facing search tool, or updated guidance to enrolled providers about how to communicate their participation to patients. That step would be a signal that the agency is prioritizing utilization, not just enrollment.

For clinical AI regulation, the marker is the substance of what emerges from the current regulator-industry engagement that STAT is tracking. If those conversations produce draft guidance or a new authorization pathway specific to adaptive AI devices, it will directly affect the compliance calculus for every enterprise buyer evaluating AI-enabled tools for clinical deployment in 2026 and beyond.